Inpatient & Residential Rehab in Southern California

By SoCal Addiction Centers Editorial Team | Last reviewed: | 17 min read Clinically Reviewed

Key Takeaways

  • “Inpatient” and “residential” are distinct clinical levels in California. Inpatient (ASAM 4.0 / 3.7-WM) is hospital or medically monitored care. Residential (ASAM 3.1, 3.3, 3.5, 3.7) is 24-hour care at a non-hospital facility. Most SoCal “inpatient rehab” facilities are technically residential under ASAM.
  • Typical length of stay is 28–90 days for residential treatment. 30-day programs are most common. ASAM clinical guidance supports 60–90 days for complex opioid or methamphetamine use disorder.
  • Private-pay cost runs $15,000–$40,000 for a 30-day program at a CARF-accredited residential facility. Luxury concierge programs in Malibu, Newport Beach, and Rancho Mirage run $40,000–$80,000+.
  • Medi-Cal DMC-ODS covers residential treatment at $0 for eligible Californians in all 6 SoCal counties. Medicare covers inpatient substance-use treatment up to a 190-day psychiatric lifetime limit.
  • The “60% rule” people ask about does not apply to SUD rehab. It applies to inpatient rehabilitation facilities (IRFs) — a separate Medicare designation for physical rehabilitation (stroke, spinal cord injury, amputation), not substance use. See below.
  • Qualifying for inpatient SUD rehab requires a clinical assessment against ASAM Criteria and, for insured patients, insurance prior authorization. Medi-Cal qualification happens through a DMC-ODS county clinician assessment.

What is inpatient rehab in California?

Inpatient rehab in Southern California is 24-hour residential treatment for substance-use disorder delivered at ASAM Level 3.1, 3.3, 3.5, or 3.7 — or at Level 4.0 in a hospital setting. Length of stay runs 28–90 days for most patients. Costs range from $0 (Medi-Cal DMC-ODS) to $80,000+ per month (luxury concierge facilities). The 1,346 DHCS-active SUD facilities in the 6 SoCal counties include residential programs at every ASAM level; 122 of those hold CARF accreditation for at least one SUD-specific program.

This page covers inpatient and residential rehab across the ASAM framework, answers the four most common questions about qualification, cost, length of stay, and the “60% rule,” and identifies CARF-accredited SoCal flagship residential facilities. Every facility named below has been cross-referenced against the DHCS public licensure dataset and the CARF provider search. We accept no referral fees.

How much does inpatient rehab cost in California?

A 30-day residential rehab program at a CARF-accredited mid-market facility in Southern California costs $15,000–$30,000 private-pay. Luxury concierge residential programs in Malibu, Newport Beach, Pasadena, and Rancho Mirage run $40,000–$80,000+ for 30 days, with some exceeding $100,000. Medi-Cal DMC-ODS covers residential treatment at zero out-of-pocket cost at contracted facilities. Commercial insurance coverage depends on the plan’s Summary of Benefits and prior authorization; under California and federal parity law, SUD residential benefits cannot be more restrictive than comparable medical-surgical benefits.

The price variation across SoCal’s residential market reflects three factors: real estate (Malibu facilities carry very different overhead than Riverside or San Bernardino), accreditation (CARF, Joint Commission, and LegitScript each impose quality standards that cost money), and what’s included (some programs bundle detox, medication, all therapy modalities, and aftercare; others price each separately). Ask for an itemized good-faith estimate under the No Surprises Act before admission.

Detailed pricing by ASAM level and county is in our cost of rehab pillar.

How do you qualify for inpatient rehab?

Qualification for residential (inpatient) rehab in California requires a clinical assessment using the ASAM Criteria. The assessment scores the patient across six dimensions — acute intoxication/withdrawal potential, biomedical conditions, emotional/behavioral/cognitive conditions, readiness to change, relapse/continued-use potential, and recovery/living environment — and places the patient at the appropriate level of care.

Residential treatment is generally clinically indicated when:

  • Withdrawal management requires 24-hour monitoring (ASAM 3.7-WM or 3.2-WM)
  • The patient has failed or is unlikely to succeed at a less-restrictive level (IOP, PHP)
  • The recovery environment (housing, social context) is unstable or actively harmful
  • Psychiatric or medical comorbidities require intensive integrated management

For insured patients, the insurance carrier conducts a medical-necessity review using ASAM Criteria or a similar clinical framework. Prior authorization is standard. Denials can be appealed internally and, if denied at the carrier level, externally through the California Department of Managed Health Care Independent Medical Review.

For Medi-Cal DMC-ODS patients, the county Drug Medi-Cal assessor conducts the placement evaluation. LA County’s SAPC Substance Use Helpline at (844) 804-7500 initiates this process for Los Angeles residents. Other counties have parallel pathways through their Behavioral Health divisions.

What is the 60% rule in inpatient rehab facilities?

The 60% rule does not apply to substance-use-disorder residential treatment. It is a Medicare classification threshold for Inpatient Rehabilitation Facilities (IRFs) — a specific category of Medicare-certified rehabilitation hospital that treats physical conditions like stroke, spinal cord injury, amputation, major multiple trauma, hip fracture, and neurological conditions.

The rule requires that at least 60% of an IRF’s admissions be for one of 13 specified conditions, none of which is substance-use disorder. Google’s “People Also Ask” surfaces this question because it is commonly searched, but it reflects a mix-up between two different senses of “inpatient rehab”: physical rehabilitation (which the 60% rule governs) and substance-use disorder treatment (which it does not).

For SUD treatment, the applicable rules are ASAM Criteria-based medical-necessity determination, state DHCS licensure, optional CARF or Joint Commission accreditation, and — for Medi-Cal — DMC-ODS county contracting. There is no analogous “60%” threshold.

How long does a patient stay in inpatient rehab?

Typical length of stay for residential SUD treatment in California is 28–90 days, with 30-day programs most common and 60–90-day stays clinically recommended for complex opioid, methamphetamine, or polysubstance-use disorder. Some patients stay longer — 120 days or more — in therapeutic community-model programs. Length of stay is clinically individualized, not pre-determined by facility marketing.

SAMHSA’s TIP 42 clinical guidance notes that outcomes improve with treatment duration, and that many patients benefit from continuous engagement across decreasing levels of care rather than a single defined admission. A patient admitted to 30-day residential, stepped down to 4 weeks of PHP, then 8 weeks of IOP, is receiving a longer and clinically deeper course of treatment than a patient completing 90 days of residential alone.

ASAM 4th edition criteria discourage fixed length-of-stay benchmarks and encourage length-of-stay decisions based on ongoing patient assessment. For insured patients, insurance carriers typically authorize in short increments (14 days initially, then renewed) based on clinical progress.

The ASAM residential levels, explained

Level 3.1 — Clinically Managed Low-Intensity Residential. 24-hour structure but limited clinical intensity. Staffed by addiction counselors and support staff. Appropriate for patients needing a stable recovery environment and structured schedule but whose clinical needs can be addressed with part-time professional care. Often overlaps operationally with “sober living with programming.”

Level 3.3 — Clinically Managed Population-Specific High-Intensity Residential. 24-hour care with higher clinical intensity, tailored to specific populations (e.g., cognitively impaired patients, older adults). Less common in SoCal than 3.1 or 3.5.

Level 3.5 — Clinically Managed High-Intensity Residential. 24-hour care with substantial clinical intensity — daily group therapy, individual therapy, psychiatric consultation. Most common “residential rehab” level in SoCal CARF-accredited facilities.

Level 3.7 — Medically Monitored Intensive Inpatient. 24-hour nursing and on-site or on-call physician coverage. Appropriate for patients with significant medical or psychiatric complexity, severe withdrawal that doesn’t require hospitalization, or complex polysubstance dependence. Passages (Malibu) and a number of other SoCal flagship facilities hold CARF accreditation at this level. Tarzana Treatment Centers operates at ASAM 3.7 across multiple LA Valley sites under active DHCS licensure; CARF SUD accreditation status should be reconfirmed directly with the operator at admission.

Level 4.0 — Medically Managed Intensive Inpatient. Hospital-level care. Provided in general hospitals, psychiatric hospitals, or specialized detox hospitals. Indicated for acute medical instability, delirium tremens, severe psychiatric crisis superimposed on SUD, or medical conditions requiring hospitalization with concurrent SUD treatment.

CARF-accredited SoCal residential flagship facilities

Our directory’s flagship tier requires current DHCS license + SAMHSA National Directory match + CARF accreditation for at least one SUD-specific program + multiple levels of care. Representative flagship residential facilities by county:

Los Angeles County:

  • Prototypes Women’s Center (Pomona) — 164-bed women-specific, Residential Treatment (BH)
  • MLK Jr. Behavioral Health Center (Los Angeles) — 99-bed, Residential Treatment (BH), county-funded
  • Socorro (Los Angeles) — 75-bed, Detox/WM Residential + Residential Treatment (BH)
  • Tarzana Treatment Centers (Tarzana) — listed tier with active DHCS licensure across multiple LA Valley sites, ASAM 3.7
  • Patterns (Hawthorne) — 35-bed, Residential Treatment (BH)
  • La Fuente Hollywood Treatment Center (Los Angeles) — multi-LOC CARF
  • Alcoholism Center for Women (Los Angeles) — 32-bed women-specific
  • Passages (Malibu) — 6-bed luxury concierge, Detox + Residential (BH)

Orange County:

  • Phoenix House Orange County (Santa Ana) — 128-bed, Detox/WM Residential

Riverside County:

  • The Ranch (Desert Hot Springs) — 46-bed, Detox/WM Residential
  • Banyan Palm Springs (Cathedral City) — ASAM Level of Care 3.5
  • Bella Monte Recovery II (Desert Hot Springs) — 38-bed, Residential Treatment (BH)
  • Hacienda Valdez (Desert Hot Springs) — 35-bed verified tier, CARF-accredited Detox/WM Residential

Ventura County:

  • Passages Ventura (Port Hueneme) — 90-bed flagship, Residential Treatment (BH) + additional LOCs
  • All In Solutions Detox (Simi Valley) — 12-bed flagship, ASAM 3.7 medically monitored intensive inpatient (RES-DETOX)
  • Note: Enlight Treatment Center (Moorpark) appears in some directory listings as a Ventura residential option. Enlight is DHCS-licensed and SAMHSA-matched, but as of our most recent review does not carry CARF accreditation for SUD-specific programs — it sits at listed tier in our directory rather than flagship or verified. See our Ventura County regional guide for the full verified-tier option set

San Diego County:

  • San Diego Freedom Ranch (Campo) — 54-bed, Residential Treatment (BH)
  • Crossroads Foundation (San Diego) — 20-bed

Full county lists are available in our facility directory.

What “inpatient” rehab looks like day to day

A typical day in residential SUD treatment at ASAM 3.5 or 3.7 looks less like a hospital and more like a structured residential program with embedded clinical treatment. The schedule is deliberately dense — a clinical goal of residential is to replace the unstructured time in which substance use happens with structured recovery-supporting time.

Morning (6:30–9:00 AM). Residents wake, attend a brief community meeting or meditation, take scheduled medications (dispensed by nursing staff — buprenorphine, antidepressants, antipsychotics, sleep medications, withdrawal-symptom meds as prescribed), have breakfast. Medication administration is observed and documented; this matters clinically because MAT adherence is the single strongest predictor of post-residential outcomes for opioid-use disorder.

Late morning (9:00 AM–12:00 PM). Primary clinical time. First group therapy session of the day — typically cognitive-behavioral therapy (CBT), motivational enhancement, trauma-focused modalities like Seeking Safety, or mutual-help groups depending on facility philosophy. 60–90 minute groups with 8–12 residents. Individual therapy sessions (50 minutes, 1–3 times per week) are scheduled in this block when the resident isn’t in group. Psychiatric consultation happens here — medication management visits with the psychiatrist or psychiatric NP, typically weekly for the first 2 weeks and then less frequently as stability improves.

Midday (12:00–1:30 PM). Lunch, free time. Some facilities include a community meeting or a brief check-in during this period. Residents may have scheduled phone calls or family contact windows.

Afternoon (1:30–5:00 PM). Second clinical block. Educational programming — relapse prevention, psychoeducation on substance-specific physiology, mindfulness-based relapse prevention (MBRP), family-systems content. Recreation and physical activity — many programs include exercise, walking, yoga, or outdoor activity as structured time. Family visits, when permitted, happen in this window. For facilities with on-site family therapy, family sessions are typically weekly and scheduled here.

Evening (5:00–10:00 PM). Dinner, 12-step or SMART Recovery or Refuge Recovery meetings (either on-site or transported to a community meeting), evening group or process time, personal time for reading/journaling/peer conversation, evening medication administration, community gratitudes or closing meeting, lights out.

Clinical-hours benchmarking. ASAM 3.5 programs typically deliver 20–30 hours of structured clinical time per week (group therapy, individual therapy, psychiatric time, educational programming). ASAM 3.7 programs deliver more — 30–40+ clinical hours — with denser physician and nursing presence throughout. “Amenity hours” (gym, chef meals, equine therapy, spa, acupuncture) are not clinical time, though they may contribute to patient engagement and retention.

Ask the facility directly for a sample weekly schedule that distinguishes clinical from non-clinical hours. A facility unwilling to produce this is selling amenities as treatment. A facility whose clinical hours fall below the ASAM benchmark for its claimed level of care is under-delivering. Residents in residential treatment should spend more than half of their waking weekday time in some form of structured clinical or recovery-supporting activity.

Insurance prior authorization for residential admission

For insured patients, residential treatment requires prior authorization (PA) from the insurance carrier before admission. This is the process that frequently causes delays or denials in accessing residential care — even when clinically indicated. Understanding how PA works is practically important for families navigating admission.

The ASAM Criteria is the medical-necessity standard. California-regulated plans and most commercial plans use the ASAM Criteria as the clinical framework for determining whether residential treatment is medically necessary. The patient’s current clinical condition is scored across the six ASAM dimensions (withdrawal, biomedical, emotional/behavioral/cognitive, readiness, relapse potential, recovery environment), and the score is matched to the appropriate level of care. A score indicating ASAM 3.5 or 3.7 is the clinical basis for residential authorization.

How PA actually works in practice:

  1. Pre-admission assessment — the admitting facility’s clinical intake team conducts an ASAM-based assessment, usually by phone or video for urgent admissions
  2. Utilization Management (UM) review — the facility submits the clinical documentation to the carrier’s UM department. A UM reviewer (typically a nurse or physician) evaluates medical necessity. Turnaround is commonly 24–72 hours for routine review, shorter for urgent admissions
  3. Initial authorization — if approved, the carrier authorizes an initial short period, typically 7–14 days. Full-stay authorization is almost never granted upfront
  4. Concurrent review — during the stay, the facility submits updates every 3–7 days demonstrating continued medical necessity. The carrier reviews and approves or denies continued-stay days
  5. Denial and appeal — if PA or continued-stay is denied, the facility (or patient) can appeal internally and, if denied, externally through California DMHC Independent Medical Review for state-regulated plans

Common denial patterns:

  • “Does not meet ASAM criteria for residential” — carrier argues IOP or PHP would be clinically sufficient
  • “Step-down not exhausted” — carrier argues patient should have tried less-restrictive care first
  • “Co-occurring condition not primarily SUD” — carrier argues the primary diagnosis is psychiatric, not substance-related

Each of these can be appealed with additional clinical documentation. Denial rates vary by carrier; anecdotal reports suggest initial denial of 15–25% of residential requests is common, with most appealed denials overturned given adequate clinical documentation.

Parity protections apply. California and federal parity law requires that SUD residential authorization processes be no more restrictive than comparable medical-surgical inpatient authorization processes. A carrier that systematically applies more restrictive UM criteria to SUD residential than to medical inpatient is likely in parity violation — grounds for a formal complaint to DMHC.

MAT during residential treatment

Medication-assisted treatment is clinically compatible with, and frequently essential to, residential SUD treatment. The era of residential programs requiring patients to taper off MAT as a condition of admission is (clinically and increasingly legally) over. Residential facilities that continue to prohibit MAT are not practicing evidence-based medicine; in some cases, they may be in violation of ADA reasonable-accommodation requirements.

Medications commonly administered in residential SUD treatment:

  • Buprenorphine (Suboxone, Subutex, Sublocade) — standard of care for opioid-use disorder. Administered sublingually daily or by monthly injection (Sublocade). Residential facilities without buprenorphine prescribing capability coordinate with the patient’s outpatient prescriber or refer to an affiliated OBOT (Office-Based Opioid Treatment) provider.
  • Methadone — can only be dispensed at DEA-registered Opioid Treatment Programs (OTPs), not at residential SUD facilities. Patients on methadone who admit to residential treatment typically continue dosing by daily transport to an affiliated OTP, or by delegated dispensing arrangements between the OTP and the residential facility.
  • Naltrexone (Vivitrol, oral naltrexone) — for both opioid and alcohol use disorder. Administered by monthly intramuscular injection or daily oral dose. Naltrexone requires a 7–10 day opioid-free period before initiation, which can align naturally with the end of a residential detox phase.
  • Disulfiram (Antabuse) — for alcohol-use disorder. Produces aversive reaction if alcohol is consumed. Daily oral dosing, often observed in residential to ensure adherence.
  • Acamprosate (Campral) — for alcohol-use disorder. Reduces post-acute alcohol craving. Three-times-daily oral dosing.

Stabilization and step-down protocols. Early residential days involve dose stabilization — adjusting medication doses to achieve symptom control with minimal side effects. By mid-residential, doses are typically stable and the focus shifts to behavioral treatment. At discharge, the patient transitions to outpatient continuation of the same medication, ideally with the outpatient prescriber identified and the first appointment scheduled before discharge.

Step-down planning should specify: continuing prescriber, prescription handoff, next appointment date, pharmacy fill arrangement for the first 30 days, and contingency plan if outpatient access is delayed. A residential facility discharging a patient on buprenorphine without a confirmed outpatient prescriber is setting up a likely relapse.

Step-down and discharge planning

Discharge from residential is not the end of treatment — it is a transition to a less-restrictive level of care. Clinical evidence consistently shows that residential patients who step down to PHP, IOP, outpatient, or structured sober living have significantly better long-term outcomes than those who discharge directly to an unstructured home environment. The discharge plan is clinically as important as the residential stay itself.

A well-constructed discharge plan includes:

  • Next level of care confirmed and scheduled — PHP, IOP, or outpatient with specific provider, appointment date, intake logistics
  • Outpatient prescriber identified — for MAT patients, who will continue prescriptions post-residential, with the first appointment scheduled
  • Housing arrangement — return to home environment, sober living placement, or transitional housing, with clinical appropriateness assessed
  • Peer-support connection — specific AA/NA home group, SMART Recovery meeting, or Refuge Recovery connection made before discharge
  • Family / support system involvement — if applicable, family therapy completion and communication plan in place
  • Crisis-response plan — what the patient does if cravings spike or relapse occurs, with named contacts and concrete steps
  • Medication continuation — 30-day supply in hand at discharge, pharmacy fill arrangement for the first month, MAT continuation confirmed

When discharge planning breaks down, patients leave residential with a vague referral (“call your IOP”) and no scheduled appointment, lose MAT access due to prescription gaps, return to the environment where substance use originated with no intervening structure, and relapse at rates considerably higher than patients with structured step-down. This is not a failure of residential treatment; it is a failure of the treatment-continuum handoff.

Ask the facility directly, before admission: “What does the step-down plan look like? Is my next-level-of-care placement confirmed before discharge or identified after?” Residential programs with strong continuing-care infrastructure confirm placement before discharge. Residential programs with weaker continuing-care infrastructure hand patients a list of outpatient providers and wish them well. The difference matters.

Questions to ask before admission

  • What specific ASAM level of care is this facility operating? (CARF and DHCS records can confirm.)
  • What FDA-approved medications are prescribed here? For OUD, are patients continued on MAT (buprenorphine/methadone/naltrexone) during residential stay?
  • How many hours of clinical time (individual therapy, group therapy, psychiatrist time) per week?
  • What is the aftercare / continuing-care plan, and is placement in the next level confirmed before discharge?
  • What is the facility’s current DHCS license status and CARF accreditation? (Verify independently — see our verification walkthrough.)
  • What is included in the quoted rate? (Medication, therapy, detox, aftercare, family services.)

Looking for a residential program that fits your situation?

Our editorial team can help identify CARF-accredited residential facilities by county, insurance network, ASAM level, and specialty population. We do not accept referral fees. Calls are informational.

Contact our editorial team →

Use the Verify Insurance tool →

Need help now? Call (310) 596-1751 for editorial guidance.

Last reviewed: 2026-04-23. ASAM Criteria references reflect the 4th edition. Cost ranges reflect DHCS license filings, CARF roster data, and published Medi-Cal DMC-ODS rate schedules at review. This page is editorial content, not medical advice.

Looking for treatment options in your area? We can help point you in the right direction. (310) 596-1751 — or request a callback.